Risk Factors Update Summary
- The company will need to raise additional funding to continue as a going concern. This might dilute existing shareholders and restrict operations.
- Cumulative net losses increased from $42.8 million to $67.8 million, with a net loss of $19.7 million in 2023.
- The company expects to rely on third parties for clinical trials, increasing costs and affecting competition.
- The company reported a decrease in cash and cash equivalents from $22.3 million to $3.6 million.
- Legal proceedings with Altor/NantCell continue, potentially resulting in substantial damages and liabilities.
- The number of full-time employees increased from 44 to 45, impacting operational costs.
- Directors and officers acquired 4% of outstanding voting stock, potentially influencing decision-making.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1828673&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.